<DOC>
	<DOCNO>NCT00465296</DOCNO>
	<brief_summary>The primary objective clinical trial ass efficacy rosiglitazone bare metal stent ( BMS ) in-stent restenosis measure late lumen loss patient metabolic syndrome . The secondary parameter evaluation efficacy binary restenosis . The tertiary objective ass effect rosiglitazone major cardiac event ( MACE ; death , MI , CABG , target vessel revascularization ) . The occurrence in-stent restenosis patient metabolic syndrome receive DES non-target lesion assess angiographically 9 month .</brief_summary>
	<brief_title>Ppar-Gamma EliminAtes Restenosis Longevity Study : PEARLS</brief_title>
	<detailed_description>This prospective , multicenter , double blind , randomize clinical trial patient present catheterization laboratory PCI ( elective setting ACS ) receive least one bare metal stent . Patients randomize 1:1 basis receive either rosiglitazone placebo 9 month . Patients follow 9 month post procedure . All patient require repeat angiogram optional IVUS analysis 9 month .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>The patient 's age &gt; /=18 year ; Patients must meet MS definition , mean patient must meet least 3 listed requirement MS : A waist circumference 40 inch men 35 inch woman ( measure across belly ) ; A blood pressure 130/85 mm Hg high ; A triglyceride level 150 mg/dl ; A fasting blood glucose level great 110 mg/dl , le 126 ; and/or A high density lipoprotein level ( HDL ) less 40 mg/dl ( men ) 50 mg/dl ( woman ) . Patients eligible PCI ; Patients must receive least one bare metal stent ; The patient stable unstable angina clinical evidence ischemia ( ECG , exercise test , etc . ) ; and/or The patient able willing conform requirement study include repeat angiographic followup 9 month , voluntarily sign Informed Consent . • Patient experience STsegment elevation myocardial infarction within precede 48 hour ; Patient must CPK CKMB &lt; 3 time upper limit normal time angioplasty enrollment ; Previously diagnose either type 1 type 2 diabetes control glucose one combination follow treatment : diet , oral antidiabetic agent , insulin ; Patient plan CABG within 9 month ; Ejection fraction &lt; 35 % ; class IIIIV CHF ; Active liver disease ( ALT &gt; 2.5 time upper limit normal ) ; Women pregnant ; A platelet count le 100,000 cells/mm3 ; Impaired renal function ( creatinine ≥2.5 mg/dL ) status post renal transplant ; Recipient heart transplant ; Patient life expectancy le 12 month ; Known allergy aspirin , clopidogrel bisulfate ( PlavixR ) ticlopidine ( TiclidR ) , heparin , bivalirudin , contrast , pioglitazone , medically manage ; Any significant medical condition , investigator 's opinion , may interfere patient 's optimal participation study ; Currently participate investigational drug another device study ; Current use thiazolidinedione ( Rosiglitazone ( Avandia ) Poiglitazone ( Actos ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>